Dannielle Appelhans Net Worth

The estimated Net Worth of Dannielle Appelhans is at least $425 Thousand dollars as of 8 December 2023. Ms Appelhans owns over 8,000 units of Rubius Therapeutics Inc stock worth over $611 and over the last 3 years she sold RUBY stock worth over $1,350. In addition, she makes $422,980 as Chief Operating Officer at Rubius Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Appelhans RUBY stock SEC Form 4 insiders trading

Ms has made over 5 trades of the Rubius Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 8,000 units of RUBY stock worth $14,320 on 8 December 2023.

The largest trade she's ever made was exercising 12,500 units of Rubius Therapeutics Inc stock on 9 August 2022 worth over $1,038. On average, Ms trades about 5,039 units every 49 days since 2021. As of 8 December 2023 she still owns at least 7,363 units of Rubius Therapeutics Inc stock.

You can see the complete history of Ms Appelhans stock trades at the bottom of the page.

Ms. Dannielle Appelhans biography

Dannielle Appelhans is the Chief Operating Officer at Rubius Therapeutics Inc.

What is the salary of Ms Appelhans?

As the Chief Operating Officer of Rubius Therapeutics Inc, the total compensation of Ms Appelhans at Rubius Therapeutics Inc is $422,980. There are 7 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.

How old is Ms Appelhans?

Ms Appelhans is 38, she's been the Chief Operating Officer of Rubius Therapeutics Inc since . There are 18 older and no younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.

What's Ms Appelhans's mailing address?

Dannielle's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.

Insiders trading at Rubius Therapeutics Inc

Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz, and Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.

What does Rubius Therapeutics Inc do?

developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.

Complete history of Ms Appelhans stock trades at Rubius Therapeutics Inc and Generation Bio Co

Rubius Therapeutics Inc executives and stock owners

Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:

• Pablo Cagnoni,
  President, Chief Executive Officer, Director
• Maiken Keson-Brookes,
  Chief Legal Officer, Corporate Secretary
• Dr. Pablo J. Cagnoni M.D., Ph.D.,
  CEO, Pres & Director
• David Epstein,
  Chairman of the Board
• Laurence A. Turka M.D.,
  Chief Scientific Officer and Head of Research & Translational Medicine
• Natalie Holles,
  Independent Director
• David R. Epstein B.Sc., M.B.A.,
  Exec. Chairman
• Dannielle Appelhans,
  Chief Operating Officer
• Anne Prener,
  Independent Director
• Jonathan Symonds,
  Independent Director
• Francis Cuss,
  Independent Director
• Catherine Sohn,
  Independent Director
• Noubar Afeyan,
  Independent Director
• Michael Rosenblatt,
  Independent Director
• Lori Melancon,
  IR Contact Officer
• Christina Coughlin,
  Chief Medical Officer
• Greg ..,
  Chief Quality Officer
• Laurence Turka,
  Chief Scientific Officer
• Kris Elverum,
  Senior Vice President - Business Development and Strategy
• Jose Carmona,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Jill Murray,
  VP & Head of HR
• Marissa Hanify,
  Director of Corp. Communications
• Maiken Keson-Brookes,
  Chief Legal Officer & Corp. Sec.
• Elhan Webb C.F.A.,
  VP of Investor Relations
• Mark J. Hernon,
  Chief Information Officer
• Spencer Fisk,
  Sr. VP & Chief Technical Operations Officer
• Jose I. Carmona,
  CFO, Principal Accounting Officer & Treasurer
• Ventures Fund Iv General Pa...,
  
• Susanne Schaffert,
  Director
• Robert Langer,
  Director
• Roger Pomerantz,
  Director
• Ventures Fund Iv General Pa...,
  
• Torben Straight Nissen,
  President
• Christopher L. Carpenter,
  Chief Medical Officer
• Dannielle Appelhans,
  CEO and President